CA3233408A1 - Imidazopyridazine il-17 inhibitor compounds - Google Patents
Imidazopyridazine il-17 inhibitor compounds Download PDFInfo
- Publication number
- CA3233408A1 CA3233408A1 CA3233408A CA3233408A CA3233408A1 CA 3233408 A1 CA3233408 A1 CA 3233408A1 CA 3233408 A CA3233408 A CA 3233408A CA 3233408 A CA3233408 A CA 3233408A CA 3233408 A1 CA3233408 A1 CA 3233408A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248566P | 2021-09-27 | 2021-09-27 | |
| US63/248,566 | 2021-09-27 | ||
| US202163273422P | 2021-10-29 | 2021-10-29 | |
| US63/273,422 | 2021-10-29 | ||
| US202263367546P | 2022-07-01 | 2022-07-01 | |
| US63/367,546 | 2022-07-01 | ||
| PCT/US2022/077001 WO2023049887A1 (en) | 2021-09-27 | 2022-09-26 | Imidazopyridazine il-17 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3233408A1 true CA3233408A1 (en) | 2023-03-30 |
Family
ID=83692741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3233408A Pending CA3233408A1 (en) | 2021-09-27 | 2022-09-26 | Imidazopyridazine il-17 inhibitor compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12173007B2 (https=) |
| EP (1) | EP4408847A1 (https=) |
| JP (1) | JP2024536869A (https=) |
| KR (1) | KR20240082369A (https=) |
| AU (1) | AU2022349687A1 (https=) |
| CA (1) | CA3233408A1 (https=) |
| CL (1) | CL2024000867A1 (https=) |
| CO (1) | CO2024003723A2 (https=) |
| DO (1) | DOP2024000051A (https=) |
| IL (1) | IL311751A (https=) |
| JO (1) | JOP20240059A1 (https=) |
| MX (1) | MX2024003772A (https=) |
| PE (1) | PE20240935A1 (https=) |
| TW (1) | TW202330530A (https=) |
| UY (1) | UY39958A (https=) |
| WO (1) | WO2023049887A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024536869A (ja) | 2021-09-27 | 2024-10-08 | ヤンセン ファーマシューティカ エヌ．ベー． | イミダゾピリダジンｉｌ－１７阻害剤化合物 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| WO2024163365A1 (en) * | 2023-01-30 | 2024-08-08 | Dice Alpha, Inc. | Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| KR20250168657A (ko) * | 2023-04-11 | 2025-12-02 | 다이스 알파, 인크. | 치환된 6-이미다조피리다진 il-17a 조정제 및 그의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752400B (zh) * | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| KR20230019507A (ko) | 2020-04-30 | 2023-02-08 | 얀센 파마슈티카 엔.브이. | Il-17의 조절제로서의 이미다조피리다진 |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| JP2024536869A (ja) | 2021-09-27 | 2024-10-08 | ヤンセン ファーマシューティカ エヌ．ベー． | イミダゾピリダジンｉｌ－１７阻害剤化合物 |
| CN116143777A (zh) | 2021-11-04 | 2023-05-23 | 四川海思科制药有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
-
2022
- 2022-09-26 JP JP2024518884A patent/JP2024536869A/ja active Pending
- 2022-09-26 AU AU2022349687A patent/AU2022349687A1/en active Pending
- 2022-09-26 UY UY0001039958A patent/UY39958A/es unknown
- 2022-09-26 US US17/935,360 patent/US12173007B2/en active Active
- 2022-09-26 CA CA3233408A patent/CA3233408A1/en active Pending
- 2022-09-26 EP EP22790174.1A patent/EP4408847A1/en active Pending
- 2022-09-26 KR KR1020247013352A patent/KR20240082369A/ko active Pending
- 2022-09-26 TW TW111136301A patent/TW202330530A/zh unknown
- 2022-09-26 WO PCT/US2022/077001 patent/WO2023049887A1/en not_active Ceased
- 2022-09-26 IL IL311751A patent/IL311751A/en unknown
- 2022-09-26 MX MX2024003772A patent/MX2024003772A/es unknown
- 2022-09-26 PE PE2024000594A patent/PE20240935A1/es unknown
-
2024
- 2024-03-14 DO DO2024000051A patent/DOP2024000051A/es unknown
- 2024-03-22 CO CONC2024/0003723A patent/CO2024003723A2/es unknown
- 2024-03-25 CL CL2024000867A patent/CL2024000867A1/es unknown
- 2024-03-26 JO JOJO/P/2024/0059A patent/JOP20240059A1/ar unknown
- 2024-10-04 US US18/906,207 patent/US20250109137A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024536869A (ja) | 2024-10-08 |
| WO2023049887A1 (en) | 2023-03-30 |
| JOP20240059A1 (ar) | 2024-03-26 |
| KR20240082369A (ko) | 2024-06-10 |
| US20230143050A1 (en) | 2023-05-11 |
| MX2024003772A (es) | 2024-06-19 |
| CO2024003723A2 (es) | 2024-04-18 |
| EP4408847A1 (en) | 2024-08-07 |
| US20250109137A1 (en) | 2025-04-03 |
| UY39958A (es) | 2023-04-28 |
| DOP2024000051A (es) | 2024-11-15 |
| US12173007B2 (en) | 2024-12-24 |
| PE20240935A1 (es) | 2024-04-30 |
| TW202330530A (zh) | 2023-08-01 |
| IL311751A (en) | 2024-05-01 |
| CL2024000867A1 (es) | 2024-09-23 |
| AU2022349687A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3233408A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| CN107949559B (zh) | 作为irak4调节剂的双环稠合杂芳基或芳基化合物 | |
| AU2019203476B2 (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| ES2718552T3 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de IRAK4 | |
| US12215111B2 (en) | Imidazopyridazine IL-17 inhibitor compounds | |
| JP5977819B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| CN111386275B (zh) | 高活性sting蛋白激动剂 | |
| CA3181793A1 (en) | Imidazopyrimidines as modulators of il-17 | |
| US9561212B2 (en) | Hepatitis C virus inhibitors | |
| WO2024201322A1 (en) | Lactam-containing imidazopyridazine il-17 inhibitor compounds | |
| EA049269B1 (ru) | Соединения ингибиторов il-17 на основе имидазопиридазина | |
| WO2025202931A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| RU2845865C2 (ru) | Нитрилсодержащие противовирусные соединения | |
| WO2025202922A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| CN118317962A (zh) | 咪唑并哒嗪il-17抑制剂化合物 | |
| HK1254323B (zh) | 作为irak4调节剂的双环稠合杂芳基或芳基化合物 | |
| HK1209284B (zh) | 嘧啶基酪氨酸激酶抑制劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240806 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240806 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250805 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250805 |